Science AI Journal
Biochemistry, Genetics and Molecular Biology · Research topic

Open research questions in BRCA gene mutations in cancer

47 unresolved questions extracted from the limitations and future-work sections of 370 BRCA gene mutations in cancer papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Although oncogenetics has been integrated into medical genetics for decades, system- atized data on the implementation and outcomes of educa- tional practices remain scarce globally (Korf 2014; Moog et al.

    Oncogenetics training in Brazilian medical genetics residency programs: current landscape and challenges · 2026 · DOI

  • Although many women have reported that they want information about their personal risk of breast cancer [24, 25], most women remain uncertain of their actual risk and tend to overestimate or underestimate their risk [25].

    Knowledge of cancer genetics and attitudes about genetic counseling and testing: a randomized trial of the Know Your Risk intervention compared to conventional genetic counseling · 2026 · DOI

  • BackgroundLarge-scale functional assays, including multiplex assays of variant effect, have substantial potential to resolve variants of uncertain significance (VUS), particularly for rare missense variants where clinical and population evidence are limited.

    'Truthsets' for clinical validation of large-scale functional assays: Practice recommendations from Cancer Variant Interpretation Group UK (CanVIG-UK) · 2026 · DOI

  • Estrogen receptor-positive breast cancer (ER+ BC) is one of the most prevalent cancers, but the evolutionary processes shaping genetic variation in ER+ BC risk are poorly understood.

    No genome-wide correlations and little shared genetic architecture between reproductive life-history traits and estrogen receptor-positive breast cancer risk · 2026 · DOI

  • Thus, the role of life-history trade-offs in shaping ER+ BC risk in European populations appears, at most, small, and the evolutionary processes giving rise to this life-threatening disease remain unclear.

    No genome-wide correlations and little shared genetic architecture between reproductive life-history traits and estrogen receptor-positive breast cancer risk · 2026 · DOI

  • Background Variants of uncertain significance (VUS) in BRCA2 remain a major challenge in the clinical management of breast cancer, particularly in Asian populations where population-specific reference data are limited.

    Functional characterization of BRCA2 variants of uncertain significance identified in Korean breast cancer patients · 2026 · DOI

  • 20-22 Consequently, inherited cancer risk is frequently under-recognized, particularly when testing strategies are restricted to a small number of genes.

    Understanding the landscape of hereditary breast and ovarian cancer testing in Brazil · 2026 · DOI

  • While PRS performance is known to be ancestry-dependent, it is not well understood how environmental context, such as that of socioeconomic status (SES), affects PRS transferability.

    Breast cancer polygenic risk score performance varies by socioeconomic status · 2026 · DOI

  • Environmental and lifestyle factors (smoking, reproductive history, hormonal therapy duration) were not integrated into the analysis despite potential modulation of BRCA1 polymorphism effects; future studies must combine genotypic data with prospectively collected environmental exposure profiles to test gene-environment interactions affecting breast cancer risk and tumor behavior.

    Evaluation of the BRCA1 GLN356Arg (rs1799950) Polymorphism in Breast Cancer: A Study in an Azerbaijani Population · 2026 · DOI

  • The study identified a genotype-tumor grade association in Azerbaijani women but did not perform multi-variant analysis incorporating other BRCA1 SNPs or regulatory polymorphisms; future investigations should employ integrated multi-variant approaches to determine whether rs1799950 effects on tumor differentiation are independent or epistatic with other common BRCA1 variants.

    Evaluation of the BRCA1 GLN356Arg (rs1799950) Polymorphism in Breast Cancer: A Study in an Azerbaijani Population · 2026 · DOI

  • Population-specific effects of rs1799950 have been documented inconsistently across Czech, Polish, Kazakh, Iranian, and Caucasian populations; systematic multiethnic comparison studies must directly compare genotype-phenotype associations within the same breast cancer subtype classification (histology, grade, stage) across these ethnic groups to identify genuine ethnic-specific genetic architecture versus methodological artifacts.

    Evaluation of the BRCA1 GLN356Arg (rs1799950) Polymorphism in Breast Cancer: A Study in an Azerbaijani Population · 2026 · DOI

  • The observed association between BRCA1 Gln356Arg genotype distribution and tumor histological grade lacks mechanistic validation; functional assays (e.g., transactivation assays, protein stability assays, DNA repair capacity measurements) must be performed to elucidate the biological basis for this variant's potential role as a tumor behavior modifier rather than a susceptibility factor.

    Evaluation of the BRCA1 GLN356Arg (rs1799950) Polymorphism in Breast Cancer: A Study in an Azerbaijani Population · 2026 · DOI

  • Critical covariates including hormonal exposure history and family history of cancer were unavailable for analysis in this Azerbaijani cohort, potentially confounding risk estimates; future studies must prospectively collect and stratify analysis by these variables to clarify whether the observed genotype-tumor grade association is independent or mediated by these factors.

    Evaluation of the BRCA1 GLN356Arg (rs1799950) Polymorphism in Breast Cancer: A Study in an Azerbaijani Population · 2026 · DOI

  • The study's sample size of 144 cases and 152 controls yielded only ~21% statistical power to detect weak-to-moderate associations (OR ≤ 1.5) for the BRCA1 Gln356Arg polymorphism; future investigations must employ larger Azerbaijani cohorts to achieve adequate power for detecting subtle genetic effects on breast cancer susceptibility.

    Evaluation of the BRCA1 GLN356Arg (rs1799950) Polymorphism in Breast Cancer: A Study in an Azerbaijani Population · 2026 · DOI

  • The youngest age group (18–39) showed the highest genetic test order rates, potentially due to heightened risk awareness from early mammography indications, yet healthy population studies have not found age-related relationships. Future research should prospectively examine how risk perception, symptom presence (mass, breast changes), and family history severity differ by age group in genetic testing decision-making among high-risk populations.

    Evaluating the effectiveness of outreach efforts and testing workflow on genetic testing participation in a high-risk population · 2026 · DOI

  • The findings demonstrate that same-building genetic testing substantially improves participation, but the study was conducted only in one health system among NCCN-identified high-risk patients. Future research should validate these workflow effectiveness findings across diverse health systems, geographic regions, and generalized unselected populations to determine generalizability beyond specialty cancer screening contexts.

    Evaluating the effectiveness of outreach efforts and testing workflow on genetic testing participation in a high-risk population · 2026 · DOI

  • The study examined overall outreach method effectiveness (email, phone, letter) but found comparable engagement across methods. Future research should experimentally test different phrasing and messaging approaches in genetic testing outreach communications to identify which language and framing strategies maximize uptake among high-risk populations, particularly among underrepresented groups.

    Evaluating the effectiveness of outreach efforts and testing workflow on genetic testing participation in a high-risk population · 2026 · DOI

  • The study found disparities in genetic test ordering by race/ethnicity and assessment language that varied significantly by testing workflow (same building vs. different building clinics), particularly affecting Black, Asian, and non-English speaking patients. Future research should investigate the specific mechanisms—including provider communication style, cultural competency, and language accessibility—that explain these equity disparities in point-of-care genetic testing delivery.

    Evaluating the effectiveness of outreach efforts and testing workflow on genetic testing participation in a high-risk population · 2026 · DOI

  • The payer variable (commercial/Medicaid/Medicare) served as an insufficient proxy for actual cost burden and insurance coverage details, which vary substantially by individual patient circumstances. Future research should directly measure patient-reported financial barriers and insurance coverage understanding to better assess how cost burden influences genetic testing uptake in high-risk populations.

    Evaluating the effectiveness of outreach efforts and testing workflow on genetic testing participation in a high-risk population · 2026 · DOI

  • Personal history of cancer was unavailable in the dataset and could not be controlled for in the analysis, yet this variable may significantly influence a patient's decision to pursue genetic testing. Future studies should explicitly collect and analyze personal cancer history as a key predictor of genetic testing participation in high-risk populations identified by NCCN guidelines.

    Evaluating the effectiveness of outreach efforts and testing workflow on genetic testing participation in a high-risk population · 2026 · DOI

  • The study used testing workflow (same building vs. different building) as a proxy for convenience and accessibility, but was unable to account for unmeasured facility-level differences such as differential staff capacity to discuss genetic testing during appointments. Future research should quantify these clinic-level implementation variations and their independent effects on genetic testing participation rates.

    Evaluating the effectiveness of outreach efforts and testing workflow on genetic testing participation in a high-risk population · 2026 · DOI

  • The perspective of primary care physicians (PCPs) regarding their role in support of genetic testing has been explored, but little is known about the expectations of patients or the PCP role once genetic test results are received.

    The primary care physician role in cancer genetics: a qualitative study of patient experience · 2010 · DOI

  • This qualitative investigation aims to identify the salient support concerns of young women with BRCA mutations, a frequently understudied population with unique developmental, psychosocial, and family needs.

    Formal and Informal Support Needs of Young Women with<i>BRCA</i>Mutations · 2008 · DOI

  • Background and Objectives: Over recent decades, germline genetic testing has become increasingly integrated into breast cancer care, yet its precise effect on the timing of surgical workflows remains incompletely defined.

    Preoperative Germline Genetic Testing and Surgical Timing in Breast Cancer: Implementation of National Reimbursement Programs: A Retrospective Cohort Study · 2026 · DOI

  • However, its role in patients carrying a germline BRCA2 mutation remains uncertain.

    The Role of Active Surveillance in Patients with Low-Risk Prostate Adenocarcinoma Harboring a Germline Brca2 Mutation: A Critical Discussion of Recent Evidence · 2026 · DOI

Most-cited papers in BRCA gene mutations in cancer

Most recent work

Find a gap in your own BRCA gene mutations in cancer sub-topic

This page shows what the BRCA gene mutations in cancer literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Biochemistry, Genetics and Molecular Biology

Gut microbiota and health
289 open questions
Single-cell and spatial transcriptomics
185 open questions
dental development and anomalies
121 open questions
Mitochondrial Function and Pathology
110 open questions
Genetic Associations and Epidemiology
106 open questions
Human-Animal Interaction Studies
105 open questions
Genomics and Chromatin Dynamics
97 open questions
Inflammatory Bowel Disease
91 open questions
47 open questions have been extracted from the limitations and future-work passages of 370 BRCA gene mutations in cancer papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.